Trial Profile
A Phase IIa, Open Label Pilot Study of Clemizole Hydrochloride Given Orally Thrice a Day, for Subjects With Hepatocellular Carcinoma That Are Either Awaiting Transplantation or Have an Unresectable Lesion
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Clemizole (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Eiger Group International
- 06 Mar 2017 New trial record